← Back to Search

Chemotherapy

Arm I: R-mabHDI and ABVD for Hodgkin's Lymphoma

Phase 3
Waitlist Available
Led By Sarath Babu, MD.
Research Sponsored by American Scitech International
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 months
Awards & highlights

Study Summary

Objective: The primary objective of the study is to evaluate the effect of R-mabHDI in patients with late stage, widespread stage and recurrent Lymphocytic Predominant Hodgkin's Lymphoma. The hypothesis is that the combination of R-mabHDI with the standard ABVD therapy in patients with late stage (Stage III and Stage IV) and recurrent stage Lymphocytic Predominant Hodgkin's Lymphoma will have a favorable outcome on the response and progress free survival. The study is also aimed at evaluating the safety of R-mabHDI . The aim of the study is to test this hypothesis by evaluating the clinical outcome in 1200 patients receiving combination of R-mabHDI once a week for 8 weeks and ABVD therapy every other week for 12 treatments.

Eligible Conditions
  • Hodgkin's Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The primary efficacy criterion is the response rates (RR) by Kaplan-Meier at 3,6,12, and 18 months.
Secondary outcome measures
Additional secondary endpoint criterion is the progress free survival (PFS) by Kaplan-Meier at 18 months.

Trial Design

2Treatment groups
Active Control
Group I: Arm I: R-mabHDI and ABVDActive Control1 Intervention
Group II: Arm II: ABVDActive Control1 Intervention

Find a Location

Who is running the clinical trial?

American Scitech InternationalLead Sponsor
5 Previous Clinical Trials
1,610 Total Patients Enrolled
Bristol-Myers SquibbIndustry Sponsor
2,642 Previous Clinical Trials
4,128,923 Total Patients Enrolled
Eli Lilly and CompanyIndustry Sponsor
2,621 Previous Clinical Trials
3,215,422 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma
2011. "Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00816959.
All > Hodgkins Lymphoma
~87 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top